JP2007512326A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007512326A5 JP2007512326A5 JP2006541190A JP2006541190A JP2007512326A5 JP 2007512326 A5 JP2007512326 A5 JP 2007512326A5 JP 2006541190 A JP2006541190 A JP 2006541190A JP 2006541190 A JP2006541190 A JP 2006541190A JP 2007512326 A5 JP2007512326 A5 JP 2007512326A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- treatment
- ethyl
- compound according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 —NH (C 1 -C 4 alkyl) Chemical group 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 8
- 230000001575 pathological effect Effects 0.000 claims 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 102000009310 vitamin D receptors Human genes 0.000 claims 4
- 108050000156 vitamin D receptors Proteins 0.000 claims 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000010392 Bone Fractures Diseases 0.000 claims 2
- 241000219198 Brassica Species 0.000 claims 2
- 235000003351 Brassica cretica Nutrition 0.000 claims 2
- 235000003343 Brassica rupestris Nutrition 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010017076 Fracture Diseases 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 208000009621 actinic keratosis Diseases 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims 2
- 208000002352 blister Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000005779 cell damage Effects 0.000 claims 2
- 208000037887 cell injury Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000002113 chemopreventative effect Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000002500 effect on skin Effects 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 235000010460 mustard Nutrition 0.000 claims 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 208000005368 osteomalacia Diseases 0.000 claims 2
- 229940075993 receptor modulator Drugs 0.000 claims 2
- 201000006409 renal osteodystrophy Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 210000002374 sebum Anatomy 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 210000004927 skin cell Anatomy 0.000 claims 2
- 230000037393 skin firmness Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- 229940069978 calcium supplement Drugs 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000011280 coal tar Substances 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000003451 thiazide diuretic agent Substances 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- KFOWWMWJKFJUTJ-UHFFFAOYSA-N CCC(CC)(c1ccc(C(N(C)C)=O)[o]1)c(cc1)cc(C)c1OCC(C(C)(C)C)=O Chemical compound CCC(CC)(c1ccc(C(N(C)C)=O)[o]1)c(cc1)cc(C)c1OCC(C(C)(C)C)=O KFOWWMWJKFJUTJ-UHFFFAOYSA-N 0.000 description 1
- MPDVTNXXSDPSQK-UHFFFAOYSA-N CCC(CC)(c1ccc(C(N(C)C)=O)[o]1)c(cc1)cc(C)c1OCC(C(C)(C)C)O Chemical compound CCC(CC)(c1ccc(C(N(C)C)=O)[o]1)c(cc1)cc(C)c1OCC(C(C)(C)C)O MPDVTNXXSDPSQK-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52401503P | 2003-11-20 | 2003-11-20 | |
| US60/524,015 | 2003-11-20 | ||
| PCT/US2004/035527 WO2005051936A1 (en) | 2003-11-20 | 2004-11-16 | Phenyl-furan compounds as vitamin d receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007512326A JP2007512326A (ja) | 2007-05-17 |
| JP2007512326A5 true JP2007512326A5 (https=) | 2007-12-27 |
| JP4750713B2 JP4750713B2 (ja) | 2011-08-17 |
Family
ID=34632855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541190A Expired - Fee Related JP4750713B2 (ja) | 2003-11-20 | 2004-11-16 | ビタミンｄ受容体調節物質としてのフェニルフラン化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7468449B2 (https=) |
| EP (1) | EP1692123B1 (https=) |
| JP (1) | JP4750713B2 (https=) |
| AT (1) | ATE396982T1 (https=) |
| CA (1) | CA2546729A1 (https=) |
| DE (1) | DE602004014188D1 (https=) |
| ES (1) | ES2307069T3 (https=) |
| WO (1) | WO2005051936A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1511740T1 (sl) * | 2002-05-29 | 2009-12-31 | Lilly Co Eli | Modulatorji vitamin d receptorja tipa fenil-tiofen |
| DE60326082D1 (de) | 2002-11-22 | 2009-03-19 | Lilly Co Eli | Modulatoren von vitamin d rezeptoren |
| CA2544857A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| ES2291981T3 (es) * | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
| US7595345B2 (en) | 2003-11-20 | 2009-09-29 | Eli Lilly And Company | Vitamin D receptor modulators |
| WO2005051936A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Phenyl-furan compounds as vitamin d receptor modulators |
| WO2005051898A2 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| DK1836151T3 (da) * | 2004-12-21 | 2009-06-02 | Lilly Co Eli | D-vitamin-receptormodulatorer |
| CA2589667A1 (en) * | 2004-12-21 | 2006-06-29 | Eli Lilly And Company | Vitamin d receptor modulators |
| US9370527B2 (en) | 2012-12-28 | 2016-06-21 | The Regents Of The University Of Michigan | Amelioration of intestinal fibrosis and treatment of Crohn's disease |
| CN103193695B (zh) * | 2013-04-22 | 2015-08-05 | 中国药科大学 | 3-苯基-3-吡咯基戊烷类衍生物及其医药用途 |
| WO2017079718A1 (en) | 2015-11-06 | 2017-05-11 | Regents Of The University Of Minnesota | Methods of forming aromatic containing compounds |
| US11236057B2 (en) | 2015-11-06 | 2022-02-01 | Regents Of The University Of Minnesota | Aromatic surfactants |
| CN106908559B (zh) * | 2015-12-23 | 2020-08-11 | 重庆华邦胜凯制药有限公司 | 卡泊三醇中间体l及相关杂质的分离与测定方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282246A (en) * | 1980-03-07 | 1981-08-04 | Pfizer Inc. | Antidiabetic furancarboxylic and thiphenecarboxylic acids |
| US6218430B1 (en) * | 1998-08-24 | 2001-04-17 | Ligand Pharmaceuticals Incorporated | Vitamin D3 mimics |
| SI1511740T1 (sl) | 2002-05-29 | 2009-12-31 | Lilly Co Eli | Modulatorji vitamin d receptorja tipa fenil-tiofen |
| DE10229456A1 (de) * | 2002-07-01 | 2004-02-05 | Wank, Rudolf, Prof. Dr.med. | Verwendung von Dopamin-Rezeptor-Agonisten zur Behandlung von Hautgeschwülsten und Warzen |
| EP1587906A2 (en) | 2003-01-10 | 2005-10-26 | Eli Lilly And Company | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators |
| WO2004063348A2 (en) | 2003-01-10 | 2004-07-29 | Eli Lilly And Company | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators |
| ES2291981T3 (es) * | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
| US7595345B2 (en) | 2003-11-20 | 2009-09-29 | Eli Lilly And Company | Vitamin D receptor modulators |
| CA2544857A1 (en) * | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| WO2005051936A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Phenyl-furan compounds as vitamin d receptor modulators |
| WO2005051898A2 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
-
2004
- 2004-11-16 WO PCT/US2004/035527 patent/WO2005051936A1/en not_active Ceased
- 2004-11-16 EP EP04810027A patent/EP1692123B1/en not_active Expired - Lifetime
- 2004-11-16 US US10/578,991 patent/US7468449B2/en not_active Expired - Fee Related
- 2004-11-16 ES ES04810027T patent/ES2307069T3/es not_active Expired - Lifetime
- 2004-11-16 JP JP2006541190A patent/JP4750713B2/ja not_active Expired - Fee Related
- 2004-11-16 CA CA002546729A patent/CA2546729A1/en not_active Abandoned
- 2004-11-16 AT AT04810027T patent/ATE396982T1/de not_active IP Right Cessation
- 2004-11-16 DE DE602004014188T patent/DE602004014188D1/de not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007512326A5 (https=) | ||
| JPWO2021020429A1 (ja) | Ｌｐａ１受容体を拮抗するウレア化合物 | |
| CA2658887A1 (en) | Fatty acid amide hydrolase inhibitors | |
| JP2001504135A (ja) | ２−アルキリデン−１９−ノル−ビタミンｄ化合物 | |
| CA2546729A1 (en) | Phenyl-furan compounds as vitamin d receptor modulators | |
| Glebocka et al. | New 2-alkylidene 1α, 25-dihydroxy-19-norvitamin D3 analogues of high intestinal activity: synthesis and biological evaluation of 2-(3 ‘-alkoxypropylidene) and 2-(3 ‘-hydroxypropylidene) derivatives | |
| CA2544501A1 (en) | Vitamin d receptor modulators | |
| CA2506891A1 (en) | Vitamin d receptor modulators | |
| CA2544517A1 (en) | Vitamin d receptor modulators | |
| Zhao et al. | Structure-dependent selective O-or C-trifluoroethylation of 1, 3-dicarbonyls by mesityl (2, 2, 2-trifluoroethyl) iodonium triflate | |
| NZ570711A (en) | 2-Substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof | |
| JP2002241271A5 (https=) | ||
| AU2012262174B2 (en) | (22E)-2-methylene-26,27-cyclo-22-dehydro-1alpha-hydroxy-19-norvitamin D3 derivatives | |
| CA2884582C (en) | Method for producing difluoro ester compound | |
| DE69806152T2 (de) | Vitamin d3 analoga mit bis-c-20-seitenketten | |
| WO2014091046A1 (es) | Intermedios versátiles y funcionalizados en la síntesis de vitamina d y nuevos derivados de vitamina d | |
| JP2008524260A5 (https=) | ||
| EP0301421A2 (de) | Neue Schwefelverbindungen, Verfahren zu ihrer Herstellung sowie Arzneimittel | |
| WO2017131144A1 (ja) | ビタミンｄ活性を有するリトコール酸誘導体 | |
| Zhang et al. | The stereospecific trifluoromethylation of α-iodo-α, β-unsaturated esters: a novel synthesis of (Z)-α-trifluoromethyl-α, β-unsaturated esters | |
| US6080879A (en) | Hexafluoro-vitamin synthesis and crystallization method, solvent and product | |
| RU2013124033A (ru) | Производное 23-ин-витамина d3 | |
| KR20240008870A (ko) | 새로운 콜레스테롤 합성 | |
| JP3039025B2 (ja) | 置換アセトアルデヒドの製造方法 | |
| Santalla et al. | A more reliable synthesis of a Gemini vitamin D analog, a potentially effective chemotherapeutic agent for the treatment of colorectal carcinomas |